Enzymatica AB (FRA:EN9) Long-Term Debt: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:EN9 Enzymatica AB FRA:EN9
41 GF Score
Price €0.17
GF Value €0.17
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Enzymatica AB Long-Term Debt?

Enzymatica AB FRA:EN9 -7.48% 41 Long-Term Debt is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:EN9 with a GF Score™ of 41/100 and a GF Value™ of €0.17 (Fairly Valued). The stock has 3 warning signs investors should review.

Enzymatica AB's Long-Term Debt for the quarter that ended in Jun. 2026 was €0.00 Mil.

Enzymatica AB's annual Long-Term Debt declined from Dec. 2023 (€1.33 Mil) to Dec. 2024 (€0.00 Mil) but then stayed the same from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€0.00 Mil).

Enzymatica AB  (FRA:EN9) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Enzymatica AB Long-Term Debt Related Terms

Enzymatica AB Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Enzymatica AB's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzymatica AB Long-Term Debt Chart

Enzymatica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1.90 1.33 0.00 0.00

Enzymatica AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:EN9
41GF Score
Enzymatica AB FRA:EN9
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €0.00 Mil mean?
Enzymatica AB (FRA:EN9) has a Long-Term Debt of €0.00 Mil as of Jun. 2026.
Is Enzymatica AB's Long-Term Debt too high?
Enzymatica AB's current Long-Term Debt is €0.00 Mil. Overall, Enzymatica AB has a GF Score™ of 41/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's Long-Term Debt compare to ZTS and UTHR?
Enzymatica AB's Long-Term Debt of €0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Enzymatica AB's current Long-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Based on GuruFocus' analysis, Enzymatica AB (FRA:EN9) is currently considered Fairly Valued. The stock's GF Value™ is €0.17, compared to a current price of €0.17 — trading 1.8% below its estimated fair value. The current Long-Term Debt is €0.00 Mil. Enzymatica AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Enzymatica AB (FRA:EN9), the current Long-Term Debt is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enzymatica AB (FRA:EN9) Overvalued in 2026?

Based on GuruFocus' analysis, Enzymatica AB stock appears to be undervalued. The current stock price of €0.17 is trading 1.8% below its estimated GF Value™ of €0.17. GuruFocus considers Enzymatica AB to be Fairly Valued.

Key valuation signals for FRA:EN9:

  • Long-Term Debt: €0.00 Mil
  • GF Value™: €0.17 vs. price of €0.17 (1.8% below fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the FRA:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enzymatica AB Business Description

Other Exchanges ENZY:Sweden
Address Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
41GF Score

Get the complete analysis for FRA:EN9

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.17
Price
€0.17
GF Value